NanoInk Awarded Grant Through NIH C3i Accell Program

Through the C3i Accell program, NanoInk Imaging will receive up to 12 months of technical development and business support, leveraging the learnings from NanoInk's work in the core C3i Program to advance the translation of our novel optical imaging technology.  Specifically, NanoInk will use the grant funds for scale-up to prepare for a large animal proof-of-concept study as an important step toward the clinic.

 

The primary objective of C3i Accell is to complete proof-of-concept studies and facilitate preparations for commercialization through start-up formation, strategic partnership, or out-licensing.  It is expected that Project Teams forming start-up companies will be well-positioned to compete for NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants to further commercial development efforts.